Study on the Effects of Raltegravir (Isentress) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers.

Trial Profile

Study on the Effects of Raltegravir (Isentress) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms RALMET-VOLHCB
  • Most Recent Events

    • 02 Apr 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Actual initiation date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top